Acerand Therapeutics, founded by industry veterans with LAV, is an innovative biotech company focusing on the discovery and development of novel best-in class and/or first-in-class drug candidates for clinical development. We have operations both in Shanghai, China as well as Indianapolis, US, to reflect its overall global strategy and business intents.

Developing new therapies for pain and traumatic brain injury.

Research and Development in Optical Devices, Medical Imaging and Nanofabrication

Offers contract viral vector production, transduced cell manufacturing, and clinical trial testing services by leveraging the expertise of the nation’s leading academic vector production and research laboratories.

Discovery and development of small molecule protein degraders as new anticancer drugs.

Health Smart Technologies, Inc. is an Indiana University based company that merges Engineering and Rehabilitation expertise to develop Smart technology advancing manual therapy.

Assisting world-class investigators to navigate the early stage challenges of translating their research into the clinic.

Developing peptide inhibitors for neuroinflammation and neurodegenerative diseases.

Developing innovative therapies devoted to having a significant impact on the delivery of microbiome therapeutics.

Treatment of Vascular complications

Founded by Prof. Chandan Sen, Dr. Ajay Seth, and Mr. Jeffrey Denune, VispalExo is a biomedical device company. VispalExo was incorporated in Delaware in June of 2020. The experimental core technology offered by VispalExo integrates natural intelligence (NI) with Artificial intelligence (AI) to develop low-cost Exoskeletal products that are designed to provide mobility to limbs affected by trauma or other neuromuscular disorders. The first product is being investigated with the goal of enabling mobility of the paralyzed hand without any surgical procedure. Such mobility may be seen within hours of the first installation. This product is currently under Beta testing and is expected to be available for advanced testing in a larger population within a year.